Ignite Creation Date:
2025-12-24 @ 1:29 PM
Ignite Modification Date:
2026-04-15 @ 8:47 PM
Study NCT ID:
NCT05803395
Status:
UNKNOWN
Last Update Posted:
2023-11-28
First Post:
2023-04-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.
Sponsor:
Gruppo Italiano Malattie EMatologiche dell'Adulto
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
CLL2423
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | UNKNOWN | View |